Glaxo Group Limited

Glaxo Wellcome Inc.

Glaxosmithkline Intellectual Property Development Limited

Biota Scientific Management Pty Ltd

Glaxogrouplimited

Simon John Fawcett MacDonald

Graham George Adam Inglis

Harry Finch

Panayiotis Alexandrou Procopiou

Michael D Dowle

Ian B Campbell

Lee Andrew Harrison

Niall Andrew Anderson

John Martin Pritchard

Gordon G Weingarten

Martin Redpath Johnson

Ashley Paul Hancock

Matthew Howard James Campbell-Crawford

Seble Lemma

Philip Alan Skone

Anthony William James Cooper

Pritom Shah

David House

Derek Anthony Demaine

Keith Biggadike

Diane Mary Coe

Julie Nicole Hamblin

Andrew McMurtrie Mason

Colin David Eldred

Gerard Martin Paul Giblin

Christine Edwards

Stephen Swanson

Xiao Qing Lewell

Garry Fenton

James Michael Woolven

Martin Edward Swarbrick

Iain McFarlane McLay

Robin Andrew Smith

Graham George Inglis

Heather Anne Barnett

Haydn Terence Jones

Steven Philip Keeling

Rachel Elizabeth Hosking

Brian David Judkins

A compound of formula (I) or a salt thereof: wherein Rrepresents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when Rrepresents an N-linked mono- or di-substituted pyrazole, Rdoes not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

A compound of formula (I) or a salt thereof: wherein Rrepresents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when Rrepresents an N-linked mono- or di-substituted pyrazole, Rdoes not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

A compound according to formula (I) wherein Ris hydrogen, cyclopropyl, or pyrazolyl, wherein said pyrazolyl is optionally substituted by one or two methyl groups; or a pharmaceutically acceptable salt thereof.

Compounds alpha v beta 6 integrin antagonists

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.

Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions

Indazoles as glucocorticoid receptor ligands

The present invention provides compounds of formula (I): a process for their preparation, pharmaceutical compositions comprising the compounds and the preparation of said compositions, intermediates and use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or skin disease.

Compounds

The present invention is directed to compounds of formula (I): whereinR represents a methyl or an ethyl groupX represents N, C&#x2014;H or C&#x2014;CHwhen X represents C&#x2014;H or C&#x2014;CH, Y represents Nwhen X represents N, Y represents C&#x2014;Hand physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.

Tetrahydro-naphthalene derivatives as glucocorticoid receptor modulators

Compounds of formula (I) or salts or solvates thereof or physiologically functional derivatives thereof are potent binders at the EP4 receptor and are of use in the treatment or prevention of conditions such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.

Indole derivatives

Compounds of formula (I), methods for their preparation and their use in the manufacture of neuraminidase inhibitor conjugates. Wherein R represents as carboxylic acid protecting group; Pand Pcan be the same or different and are selected from amine protecting groups; Prepresents a protecting group for 1, 2 diols; and LG represents a leaving group 

Intermediates for preparing neuraminidase inhibitor conjugates

According to the invention are provided compounds of formula (I) (relative stereochemistry indicated) wherein R,, R,and R,are as defined in the specification. Compounds of formula (I) are useful inter alia in the treatment of inflammatory diseases of the respiratory tract.

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

There are described according to the invention, processes for making compounds of formula (XXVIII),(relative stereochemistry indicated), wherein P,is as defined in the specification.

According to the invention there are provided Hexahydro-Pyrrolo&lsqb;3,4-b&rsqb;pyrrol-2-one compounds of formula (1), (relative stereochemistry indicated), wherein R,, R,and R,are as defined in the specification. Compounds of formula (1) are useful inter alia in the treatment or chronic bronchitis.

Pyrrolopyrrolone derivatives

Growing community of inventors

Stevenage, United Kingdom

Simon John Fawcett MacDonald